Title: Barriers to adherence to antimicrobial stewardship post-prescription review and feedback for broad-spectrum antimicrobial agents: a nested case-control study

Authors:

Akane Takamatsu, MD\textsuperscript{1,2}, Kenta Yao, MD\textsuperscript{1}, Shutaro Murakami, BSP\textsuperscript{2}, Yasuaki Tagashira, MD PhD\textsuperscript{1,2}, Shinya Hasegawa, MD\textsuperscript{1,2}, and Hitoshi Honda, MD PhD\textsuperscript{1,2}

Institutions:

1. Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
2. Department of Infection Control, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

Institutional addresses:

1. Division of Infectious Diseases, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo, Japan.
2. Department of Infection Control, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo, Japan.

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Email addresses:

Akane Takamatsu: chrise_type@hotmail.com; Kenta Yao: kentayao.tmdu@gmail.com;

Shutaro Murakami: shuutaromura@gmail.com; Yasuaki Tagashira: y.tagashira@gmail.com;

Shinya Hasegawa: hase.pokkun@gmail.com; Hitoshi Honda: hhhhonda@gmail.com

Corresponding author: Hitoshi Honda, MD, PhD

Alternate corresponding author: Akane Takamatsu, MD

Keywords: Antimicrobial stewardship program, broad-spectrum antimicrobials,
post-prescription review and feedback, audit and feedback, adherence

Summary of the article’s main point:

The present study investigated factors associated with non-adherence to post-prescription review and feedback (PPRF) recommendations and found that patients with a severe disease condition and those with a recent history of hospitalization frequently continued to receive broad-spectrum antimicrobials against PPRF recommendations.
Abstract

Background

Post-prescription review and feedback (PPRF) is one of the most common strategies in antimicrobial stewardship program (ASP) intervention. However, disagreements between the prescribers and ASP personnel can occur. The aim of the present study was to identify the factors associated with non-adherence to PPRF intervention.

Methods

The present retrospective nested case-control study was performed at a tertiary care center, which has been conducting a once-weekly PPRF for carbapenems and piperacillin/tazobactam since 2014. Non-adherence to ASP recommendations was defined as the failure of the primary care team to modify or stop antimicrobial therapy 72 hours after the issuance of PPRF recommendations. Factors associated with non-adherence to PPRF intervention were identified using multivariate logistic regression analysis.

Results

In total, 2,466 instances of PPRF in 1,714 cases between April 2014 and September 2019 were found. The non-adherence rate was 5.9%, and 44 cases were found in which carbapenems or piperacillin/tazobactam continued to be used against PPRF recommendations. Factors associated with non-adherence to PPRF recommendations were a previous history of hospitalization within 90 days (adjusted odds ratio [aOR]: 2.62, 95% confidence interval
1.18 - 5.81) and a rapidly fatal McCabe score at the time of PPRF intervention (aOR: 2.87, 95% CI: 1.18 - 6.98). A review of the narrative comments in the electronic medical records indicated that common reasons for non-adherence were “the patient was sick” (n=12; 27.3%), and “the antimicrobial seemed to be clinically effective” (n=9; 20.5%).

Conclusions

Non-adherence to PPRF recommendations was relatively uncommon at the study institution. However, patients with a severe disease condition frequently continued to receive broad-spectrum antimicrobials against PPRF recommendations. Understanding physicians’ cognitive process in non-adherence to ASP recommendations and ASP interventions targeting medical subspecialties caring for severely ill patients is needed to improve ASP.
Introduction

Antimicrobials are commonly used in the acute care setting. Recent studies found that around 30% of patients received antimicrobials during hospitalization,\textsuperscript{1,2} and 33% of antimicrobial prescriptions were considered inappropriate.\textsuperscript{3} A multicenter study in Japan revealed an inappropriate antimicrobial use rate of approximately 40% for the inpatient population at acute care hospitals.\textsuperscript{4} The overuse of antimicrobials has contributed to the development of resistant organisms, hampering infection control and treatment.\textsuperscript{5} The antimicrobial stewardship program (ASP) in healthcare settings is essential for optimizing antimicrobial therapy to improve individual patient care, reduce hospital costs, and prevent the emergence of antimicrobial resistance.

Two core strategies are recommended for the healthcare setting: preauthorization and post-prescription review and feedback (PPRF).\textsuperscript{6} PPRF alone or limited PPRF also showed effectiveness in decreasing inappropriate antimicrobial prescription and reducing antimicrobial resistance.\textsuperscript{7-10} These strategies, however, are labor-intensive, and institutions with limited sources may encounter difficulties in implementing them.

While PPRF may generally be considered to be effective, disagreements between the prescribers and ASP personnel can arise. Previous studies evaluating the efficacy of PPRF showed that non-adherence to ASP recommendations ranged from 15% to 33%.\textsuperscript{11-13} The barrier to appropriate antimicrobial prescription is likely to be multifactorial.\textsuperscript{12,13} Although
prescriber-related factors (e.g., knowledge and attitude) and patient-related factors (e.g., underlying conditions and disease severity) were associated with non-adherence in previous studies. Factors may differ among healthcare systems. The aim of the present study was to investigate the frequency of non-adherence to PPRF intervention and to identify the factors associated with non-adherence to recommendations against the use of broad-spectrum antimicrobials at a Japanese tertiary care center.

Methods

Study design and setting

The present retrospective nested case-control study was conducted at Tokyo Metropolitan Tama Medical Center, a 790-bed tertiary care center with 29 subspecialties, including a division of infectious diseases and an ASP. All the physicians in the division of infectious diseases were also actively involved in antimicrobial stewardship activities.

An ASP run by a multidisciplinary team was implemented in April 2014. The team consisted of two infectious disease physicians, two infectious disease fellows, one clinical pharmacist, one microbiology laboratory technician, and an infection control nurse. Before its implementation, there was no form of antimicrobial stewardship except for an infectious disease (ID) consultation service, which was begun in July 2013 by a physician with American Board of Internal Medicine Infectious Diseases certification. Details of the PPRF
intervention at the study institution have been described elsewhere. A clinical pharmacist routinely monitored all inpatient antimicrobial consumption, and all hospital wards were included in the PPRF intervention. All the members attended a once-weekly PPRF meeting. Once the appropriateness of broad-spectrum antimicrobials (i.e., carbapenems and piperacillin/tazobactam) was determined, their use was documented in each patient’s electronic medical records (EMR). Carbapenem use was considered appropriate for the treatment of febrile neutropenia, infections only susceptible to carbapenem antimicrobials, and infections for which carbapenems were conventionally considered to be first-line agents whereas piperacillin/tazobactam use was considered appropriate for the following: treatment of febrile neutropenia, empiric therapy for healthcare-associated infections (HAIs), definitive therapy for HAIs for which piperacillin/tazobactam was considered the best choice based on clinical conditions and culture results, and polymicrobial infections for which piperacillin/tazobactam was the preferred therapy.

For all patients with inappropriate antimicrobial use, our recommendations on antimicrobial use were issued by the designated ID physician directly contacting the primary care providers by telephone and through documentation in the EMR. Non-adherence to ASP recommendations was defined as the failure of the primary care team to modify or stop antimicrobial therapy 72 hours or more after the issuance of the PPRF recommendations.
Participants

Patients older than 18 years who received a once-weekly PPRF were included. From our PPRF database, cases of non-adherence to PPRF recommendations between April 2014 and September 2019 were first identified, then three controls per case consisting of patients for whom the prescribers accepted the PPRF recommendations were randomly selected from the cohort in the same period to minimize selection bias. Cases in which ID consultation was performed within 72 hours after PPRF and cases in which an ID physician recommended continuing broad-spectrum antimicrobial administration were excluded. The relevant patients in the case group were excluded before selecting the controls. If patients received multiple PPRF in one episode, only the first was included. Multiple episodes in the same patient were counted individually. Patient consent was waived because the study was retrospective, involved no interaction with patients, and PPRF was one of the ASP interventions routinely performed as part of a hospital-wide quality improvement project. The institutional review board at the study institution approved this study.

Data collection

All data on ASP intervention were prospectively collected whereas individual data on cases of non-adherence to ASP were retrospectively collected by a manual review of the EMR. Data on patient demographics, preexisting medical conditions, medical exposures, colonization of multidrug-resistant organisms (MDRO), source of infections, antimicrobial
treatment information, laboratory information, patients’ condition at the time of PPRF, including their McCabe score,\textsuperscript{16} prescriber information (i.e., department, postgraduate year [PGY], decision-maker), length of stay (LOS), in-hospital mortality, re-admission, and adverse events after PPRF were collected. The reasons for non-adherence were also collected by reviewing each patient’s EMR. MDRO in the study institution included methicillin-resistant \textit{Staphylococcus aureus}, vancomycin-resistant \textit{Enterococci}, carbapenem-resistant \textit{Enterobacteriaceae}, multidrug-resistant (MDR) \textit{Acinetobacter} spp., MDR \textit{Pseudomonas} spp., and extended-spectrum cephalosporin-resistant organisms based on the definition of the US Centers for Disease Control and Prevention (CDC).\textsuperscript{17} Each patient had a representative primary care provider (PCP) except patients in the department of critical care medicine and some medical or surgical departments (e.g., general internal medicine and general surgery) in which care was administered by multiple team members. A prescriber was defined as the patient’s PCP or a physician who prescribed broad-spectrum antimicrobial agents at the time of a PPRF. Adverse events after a PPRF included \textit{Clostridioides difficile} infection (CDI) developing within three months of antimicrobial administration, acute kidney injury (AKI) developing within one month of antimicrobial administration, and MDRO acquisition confirmed by clinical culture specimens during index hospitalization. The definition of CDI and AKI was based on the clinical practice guidelines of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America
(SHEA),\textsuperscript{18} and Kidney Disease: Improving Global Outcomes.\textsuperscript{19}

\textbf{Statistical analysis}

In univariate analyses, categorical variables were compared using the chi-square test or Fisher’s exact test as appropriate, and continuous variables were compared using the Mann-Whitney U test. All tests for significance were two-tailed, with $P < 0.05$ considered significant.

Multivariate logistic regression was done to predict the factors associated with non-adherence to PPRF intervention. Factors related to non-adherence in previous studies, including patients’ underlying illness (e.g., diabetes mellitus),\textsuperscript{12} and prescriber-related factors, including surgeons\textsuperscript{14} and senior physicians,\textsuperscript{13} were forced into the final model. Additionally, for factors with $P < 0.1$ on univariate analysis with clinical plausibility, we assessed multicollinearity by examining the variance inflation factors and two-by-two tables to ensure the independence of the explanatory variables. Variables were retained in the final model if $P < 0.05$. The Hosmer-Lemeshow test was used to assess goodness of fit for the logistic regression model. All analyses were performed using Stata version 15 (StataCorp, College Station, TX, USA).
Results

In total, 2,466 PPRF interventions in 1,714 cases were found in the cohort between April 2014 and September 2019. Of the 2,466 PPRF interventions, 854 involved inappropriate use, and 50 involved non-adherence (5.9%). The non-adherence rate by year was 12.3% (2014), 6.8% (2015), 7.9% (2016), 4.2% (2017), 4.6% (2018), and 3.7% (2019). After excluding two PPRF interventions with ID consultation obtained within 72 hours after a PPRF recommendation to continue using broad-spectrum antimicrobial agents and four PPRF interventions within the same episode, 44 cases of continued carbapenem or piperacillin/tazobactam use against PPRF recommendations were subsequently identified. In addition, 132 controls were selected. The median day of carbapenem or piperacillin/tazobactam use between the initial antimicrobial administration date and the PPRF date was five days (interquartile range: 4-7 days). The demographic, clinical, and laboratory characteristics of the patients at the time of PPRF in both the case and control groups are shown in Table 1. In the non-adherence group, the percentage of patients with a history of hospitalization, chemotherapy, and steroid use before index hospitalization was greater (68.2% vs. 39.4%, 18.2% vs. 5.3%, 45.5% vs. 15.9%), and more patients had a rapidly fatal McCabe score at the time of PPRF intervention (47.7% vs. 27.7%).

Hematology/oncology (n=41; 23.3%), gastroenterology (n=29; 16.5%), general surgery (n=26; 14.8%), and critical care medicine (n=25; 14.2%) accounted for more than 60% of all...
departments. Intra-abdominal infections were the most common \( n=38; 21.6\% \), followed by febrile neutropenia \( n=23; 13.1\% \). The details of the infection sources are shown in Supplementary Figure 1. In the 44 cases with non-adherence to PPRF recommendations, the main reasons documented in the EMR were “the patient was sick” \( n=12; 27.3\% \), “the antimicrobial seemed to be clinically effective” \( n=9; 20.5\% \), “the patient was immunocompromised” \( n=7; 15.9\% \), “the patient was colonized with an MDRO” \( n=4; 9.1\% \), and “the patient was scheduled to be transferred or discharged soon” \( n=4; 9.1\% \) (Table 4).

Hematology/oncology \( n=16; 36.4\% \), critical care medicine \( n=9; 20.5\% \), and gastroenterology \( n=8; 18.2\% \) accounted for more than 70\% of the non-adherence group. Of the 44 non-adherence cases, 11 (25\%) involved care given by three hematology/oncology physicians. In the multivariate model, the factors independently associated with non-adherence to PPRF intervention were a previous history of hospitalization within 90 days (adjusted odds ratio [aOR]: 2.62, 95\% confidence interval [CI]: 1.18-5.81) and a rapidly fatal McCabe score at the time of PPRF intervention (aOR: 2.87, 95\% CI: 1.18-6.98) (Table 2). There was no statistical difference in the incidence of adverse events and key clinical outcomes related to antimicrobial practice between the two groups (Table 3).
Discussion

The present study described the frequency of non-adherence to PPRF recommendations for broad-spectrum antimicrobial use at a tertiary care center and demonstrated that patient-related factors, including a previous history of hospitalization and higher severity of illness at the time of PPRF intervention, were independently associated with non-adherence even after adjusting for previously reported factors associated with non-adherence. Although the overall non-adherence rate was low at the study institution, some unique findings related to continuing broad-spectrum antimicrobial use against PPRF recommendations provided a better understanding of prescribing behaviors in the treating physicians.

As seen in Table 2, a previous history of hospitalization within 90 days and a rapidly fatal McCabe score at the time of PPRF intervention were independent factors in non-adherence. A previous history of hospitalization was thought to be a risk factor for acquiring MDRO.\(^{20}\) One possible explanation for the history of hospitalization as a factor in non-adherence is that physicians tend to continue prescribing broad-spectrum antimicrobial agents out of concern to prevent HAIs caused by MDROs. Moreover, physicians may have taken patients’ previous history of MDRO colonization into account when deciding on the type of antimicrobial therapy because MDRO colonization persists for more than a year in some patients.\(^{21}\) Even though our ASP personnel reviewed the EMR carefully to decide the appropriateness of antimicrobial use based on predetermined criteria, there may have been a
discrepancy with regard to antimicrobial treatment between the ASP personnel and prescribers who cared for patients at their bedside.

The rapidly fatal McCabe score at the time of PPRF intervention is likely to be an indicator of greater disease severity. The McCabe score is normally used to estimate the likelihood of survival in patients with gram-negative bacteremia and was also shown to be an even better predictor of survival in other infections. Critically ill patients tend to receive prolonged broad-spectrum antimicrobials, which are often unnecessary or inappropriate, and antimicrobial overtreatment is a frequent phenomenon in critical care settings. In the current study, more than one-fourth of the non-adherence cases involved the continued use of broad-spectrum antimicrobials due to the severity of the patients’ condition.

Previous studies have revealed that physicians caring for critically ill patients perceived antimicrobial resistance (AMR) to be a substantial problem, and their perception of ASP seemed favorable, but fear of treatment failure or a worse clinical outcome in critically ill patients may discourage physicians from de-escalating or discontinuing antimicrobial therapy despite inappropriate use. Hence, ASP in critical care settings is particularly important. Although these situations differed from those in the present study, rational antimicrobial use may not worsen clinical outcomes in these contexts, and PPRF can be safely implemented in the intensive care unit. In addition, handshake stewardship, characterized by a rounding-based, in-person approach to feedback, was effective in reducing
antimicrobial use. Multifaceted approaches, including education, direct communication, timely ID consultation, sharing of surveillance data, and PPRF, may be the key to promoting ASP further among physicians caring for severely ill patients.

In this study, a relatively low rate of non-adherence was observed from the start of PPRF. Previous studies revealed that the non-adherence rate ranged from 15% to 33%. The main possible explanation for the lower non-adherence rate in the present study compared with previous studies was that the authors telephoned the prescribing physicians directly whenever they detected inappropriate use, thus improving understanding of the importance of appropriate antimicrobial prescription among treating physicians. Ironically, the ID physicians' act of telephoning the prescribing physicians may have contributed to the relatively high adherence rate due to the cultural background of paternalistic leadership common in Asia, including Japan. In addition, we had already embarked on other ASP, such as reviewing and monitoring sterile site cultures and surveilling antimicrobial consumption prior to initiating PPRF. A study conducted in five academic centers concluded that PPRF was more effective when performed in a hospital with an established ASP. In the current study, non-adherence to PPRF intervention slowly decreased from 12.3% in 2014 to 3.7% in 2019, suggesting the value of maintaining ASP and establishing PPRF as a part of a hospital-wide initiative.
With regard to the characteristics of individual prescribers in the non-adherence group, physicians in hematology/oncology and critical care medicine who may have treated critically ill patients accounted for more than half the cases of non-adherence. Fear of possible, future complications and anxiety about overlooking an infection were reported as prescriber-related factors of inappropriate antimicrobial use\textsuperscript{32-36} and may explain why more than 40\% of non-adherence cases in our study showed continued use of broad-spectrum antimicrobials against PPRF recommendations due to the severity of the patients’ condition or their immunocompromised status. Moreover, it is noteworthy that the prescribing physicians in one-fourth of the non-adherence cases were frequently the same hematology/oncology physicians. Antimicrobial stewardship intervention for patients with hematologic malignancies is indeed challenging due to the complexity of the cases, the patients’ immunocompromised status, and high mortality related to invasive infections.\textsuperscript{37} One possible reason for non-adherence in such cases is that these physicians in hematology/oncology might have had a strong opinion about their antimicrobial prescription policy and felt PPRF to be an unwelcome intrusion. One reason for a number of non-adherence cases (i.e., continuing broad-spectrum antimicrobial use against PPRF recommendations) was the perceived clinical effectiveness of the agents. This subjective assessment may have derived from prescribers’ past clinical experience. In fact, the inertia of current practices was thought to reflect a lack of provider motivation to change inappropriate
antimicrobial use. Such ‘outlier’ physicians may have had legitimate reasons for non-adherence which may not always have been recorded in the EMR. However, it is equally possible that these physicians were more conservative in their views and thus less inclined to adopt innovative strategies, as seen in the diffusion of innovation theory discussed by Rogers. Although the prescribers in the present study were not directly interviewed because the study was retrospective, their knowledge (e.g., familiarity, insight, and ignorance) and attitudes (e.g., fear, anxiety, and inertia) may be considered to be potentially modifiable factors. Indeed, changing the behavior of such individuals is challenging, but direct face-to-face communication with evidence-based recommendations may facilitate understanding the prescribers’ thought processes and open the way for possible educational resolution of differences in opinion. Showing an effort to understand physicians’ thought processes via nudge psychology and emphasizing that the goal of ASP is to maximize benefits both to the prescribing physicians and the patients may also be useful. In addition, involving a colleague from the same department as the outlier physicians to help advocate antimicrobial stewardship initiatives can lead to the successful promotion of ASP.

Adverse events and outcome measures between the two groups in this study did not differ statistically, presumably due to the small sample size. Although the rapidly fatal McCabe score at the time of PPRF intervention was independently associated with non-adherence, no statistical difference in the overall mortality rate or re-admission rate was
observed between the groups, indicating that PPRF intervention did not cause any harmful events in the patients and can be safely implemented.

This study has some limitations. First, because it was a single-center, retrospective study, the findings may have limited generalizability, and the collected data may be limited despite the use of standardized definitions and data collection forms. Moreover, some cases may not have been recorded in the EMR, and several potentially modifiable prescriber-related factors described in the previous studies may have been overlooked. Also, even after adjusting for known predisposing factors, other unmeasured factors may have contributed to non-adherence to PPRF intervention.

Conclusions

Although in general, non-adherence to PPRF recommendations is relatively common, and the reasons for it are generally multifactorial across institutions, non-adherence to PPRF recommendations was relatively uncommon at the study institution, suggesting the importance of the robustness of the existing ASP infrastructure in enhancing the effectiveness of PPRF. Severely ill patients and those with a recent history of hospitalization frequently continued to receive broad-spectrum antimicrobials against PPRF recommendations.
Understanding physicians’ psychology and individual interventions by targeting medical subspecialties caring for severely ill patients using nudge psychology along with hospital-wide ASP is warranted to promote ASP further.

**Ethics and ethics approval and consent to participate:** The institutional review board at Tokyo Metropolitan Tama Medical Center approved this study.

**Consent for publication:** Not applicable

**Authors' contributions:** AT and HH designed the study protocol. AT, SM, SH, YT, and HH ran the antimicrobial stewardship program. AT, SM, and KY collected the data. AT and HH performed the data analysis. AT drafted and revised the manuscript. SM, KY, SH, YT, and HH performed the critical review. All the authors contributed to the final version of manuscript.

**Availability of data and material:** The datasets analyzed for the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** None
Acknowledgements: We thank the staff of the Department of Microbiology at Tokyo Metropolitan Tama Medical Center for their management of the antimicrobial susceptibility data. We are indebted to James R. Valera for his assistance with editing the manuscript.
References

1. Lee C, Walker SA, Daneman N, et al. Point prevalence survey of antimicrobial utilization in a Canadian tertiary-care teaching hospital. *J Epidemiol Glob Health.* Jun 2015;5(2):143-150.

2. Zingg W, Metsini A, Gardiol C, et al. Antimicrobial use in acute care hospitals: national point prevalence survey on healthcare-associated infections and antimicrobial use, Switzerland, 2017. *Euro Surveill.* Aug 2019;24(33).

3. Gurtler N, Erba A, Giehl C, Tschudin-Sutter S, Bassetti S, Osthoff M. Appropriateness of antimicrobial prescribing in a Swiss tertiary care hospital: a repeated point prevalence survey. *Swiss Med Wkly.* Oct 7 2019;149:w20135.

4. Komagamine J, Yabuki T, Kobayashi M, Okabe T. Prevalence of antimicrobial use and active healthcare-associated infections in acute care hospitals: a multicentre prevalence survey in Japan. *BMJ Open.* Jun 28 2019;9(6):e027604.

5. The Centers for Disease Control and Prevention. ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf Accessed 13 March 2020.

6. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society
7. LaRocco A, Jr. Concurrent antibiotic review programs--a role for infectious diseases specialists at small community hospitals. *Clin Infect Dis.* Sep 1 2003;37(5):742-743.

8. Elligsen M, Walker SA, Pinto R, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. *Infect Control Hosp Epidemiol.* Apr 2012;33(4):354-361.

9. Honda H, Murakami S, Tagashira Y, et al. Efficacy of a Postprescription Review of Broad-Spectrum Antimicrobial Agents With Feedback: A 4-Year Experience of Antimicrobial Stewardship at a Tertiary Care Center. *Open Forum Infect Dis.* Dec 2018;5(12):ofy314.

10. Vettese N, Hendershot J, Irvine M, Wimer S, Chamberlain D, Massoud N. Outcomes associated with a thrice-weekly antimicrobial stewardship programme in a 253-bed community hospital. *J Clin Pharm Ther.* Oct 2013;38(5):401-404.

11. Cosgrove SE, Seo SK, Bolon MK, et al. Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention. *Infect Control Hosp Epidemiol.* Apr 2012;33(4):374-380.

12. Horton CD, Rawlins MDM, Manning L, Ingram PR. Non-adherence to antimicrobial stewardship prospective audit and feedback advice: Risk factors and clinical
consequences. *J Infect Chemother.* Jun 2019;25(6):485-488.

13. Bio LL, Kruger JF, Lee BP, Wood MS, Schwenk HT. Predictors of Antimicrobial Stewardship Program Recommendation Disagreement. *Infect Control Hosp Epidemiol.* Jul 2018;39(7):806-813.

14. Duane TM, Zuo JX, Wolfe LG, et al. Surgeons do not listen: evaluation of compliance with antimicrobial stewardship program recommendations. *Am Surg.* Dec 2013;79(12):1269-1272.

15. Tagashira Y, Horiuchi M, Tokuda Y, Heist BS, Higuchi M, Honda H. Antimicrobial stewardship for carbapenem use at a Japanese tertiary care center: An interrupted time series analysis on the impact of infectious disease consultation, prospective audit, and feedback. *Am J Infect Control,* Jun 1 2016;44(6):708-710.

16. McCabe WR, Jackson GG. Gram negative bacteremia: I. Etiology and ecology. *Arch Intern Med.* 1962;110(6):845–855.

17. The Centers for Disease Control and Prevention. Antimicrobial Resistant Phenotype Definitions. Available at: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/phenotype_definitions.pdf

Accessed 13 March 2020.

18. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious
Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis.* Mar 19 2018;66(7):e1-e48.

19. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract.* 2012;120(4):c179-184.

20. Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. *Clin Infect Dis.* Feb 15 2012;54(4):470-478.

21. Banach DB, Bearman G, Barnden M, et al. Duration of Contact Precautions for Acute-Care Settings. *Infect Control Hosp Epidemiol.* Feb 2018;39(2):127-144.

22. Delodder F, Que YA, Revelly JP, Eggimann P, the Staff of the Service of Adult Intensive Care Medicine (SMIA). McCabe score as a strong determinant of septic shock-related mortality. *BMC Proc.* 2011;5(Suppl 6):74.

23. Martin-Löeches I, Leone M, Madach K, Martin C, Einav S. Antibiotic therapy in the critically ill - expert opinion of the Intensive Care Medicine Scientific Subcommittee of the European Society of Anaesthesiology. *Eur J Anaesthesiol.* Apr 2017;34(4):215-220.

24. Lepape A, Jean A, De Waele J, et al. European intensive care physicians' experience of infections due to antibiotic-resistant bacteria. *Antimicrob Resist Infect Control.* 2020;9:1.
25. Steinberg M, Dresser LD, Daneman N, et al. A National Survey of Critical Care Physicians’ Knowledge, Attitudes, and Perceptions of Antimicrobial Stewardship Programs. *J Intensive Care Med.* Jan 2016;31(1):61-65.

26. DiazGranados CA. Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes. *Am J Infect Control.* Aug 2012;40(6):526-529.

27. Hurst AL, Child J, Pearce K, Palmer C, Todd JK, Parker SK. Handshake Stewardship: A Highly Effective Rounding-based Antimicrobial Optimization Service. *Pediatr Infect Dis J.* Oct 2016;35(10):1104-1110.

28. Emmerson M. Antibiotic usage and prescribing policies in the intensive care unit. *Intensive Care Med.* 2000;26 Suppl 1:S26-30.

29. Raineri E, Pan A, Mondello P, Acquarolo A, Candiani A, Crema L. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. *Am J Infect Control.* May 2008;36(4):283-290.

30. Salerno SM, Hurst FP, Halvorson S, Mercado DL. Principles of effective consultation: an update for the 21st-century consultant. *Arch Intern Med.* Feb 2007;167(3):271-275.

31. Cheng BS, Boer D, Chou LF, et al. Paternalistic Leadership in Four East Asian
Societies: Generalizability and Cultural Differences of the Triad Model. *Journal of Cross-Cultural Psychology.* 2014;45(1):82-90.

32. Thompson W, Tonkin-Crine S, Pavitt SH, et al. Factors associated with antibiotic prescribing for adults with acute conditions: an umbrella review across primary care and a systematic review focusing on primary dental care. *J Antimicrob Chemother.* Aug 1 2019;74(8):2139-2152.

33. Schouten JA, Hulscher ME, Natsch S, Kullberg BJ, van der Meer JW, Grol RP. Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. *Qual Saf Health Care.* Apr 2007;16(2):143-149.

34. Kumar S, Little P, Britten N. Why do general practitioners prescribe antibiotics for sore throat? Grounded theory interview study. *BMJ.* Jan 18 2003;326(7381):138.

35. Livorsi D, Comer A, Matthias MS, Perencevich EN, Bair MJ. Factors Influencing Antibiotic-Prescribing Decisions Among Inpatient Physicians: A Qualitative Investigation. *Infect Control Hosp Epidemiol.* Sep 2015;36(9):1065-1072.

36. Kotwani A, Wattal C, Katewa S, Joshi PC, Holloway K. Factors influencing primary care physicians to prescribe antibiotics in Delhi India. *Fam Pract.* Dec 2010;27(6):684-690.

37. Robilotti E, Holubar M, Seo SK, Deresinski S. Feasibility and applicability of antimicrobial stewardship in immunocompromised patients. *Curr Opin Infect Dis.*
38. Goldstein EJ, Goff DA, Reeve W, et al. Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines. *Clin Infect Dis.* Aug 15 2016;63(4):532-538.

39. Rogers EM. *Diffusion of Innovations.* 5th ed: Simon and Schuster; 2003.

40. Teixeira Rodrigues A, Ferreira M, Pineiro-Lamas M, Falcao A, Figueiras A, Herdeiro MT. Determinants of physician antibiotic prescribing behavior: a 3 year cohort study in Portugal. *Curr Med Res Opin.* May 2016;32(5):949-957.

41. Spellberg B. Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use. *JAMA Intern Med.* Mar 2014;174(3):432-433.

42. Saint S, Kowalski CP, Banaszak-Holl J, Forman J, Damschroder L, Krein SL. How active resisters and organizational constipators affect health care-acquired infection prevention efforts. *Jt Comm J Qual Patient Saf.* May 2009;35(5):239-246.

43. Krein SL, Kowalski CP, Harrod M, Forman J, Saint S. Barriers to reducing urinary catheter use: a qualitative assessment of a statewide initiative. *JAMA Intern Med.* May 27 2013;173(10):881-886.
## Table 1. Clinical characteristics

|                              | Non-adherence (n=44) | Adherence (n=132) | P value |
|------------------------------|----------------------|-------------------|---------|
| **Patient demographics**     |                      |                   |         |
| Age, median, (IQR) years     | 68 (59-79)           | 71 (59-80)        | 0.546   |
| Male sex, n (%)              | 26 (59.1)            | 74 (56.1)         | 0.861   |
| Charlson comorbidity index score, n (%) | 0.128              |                   |         |
| <2                           | 5 (11.4)             | 34 (35.8)         |         |
| 2-5                          | 30 (68.2)            | 78 (59.1)         |         |
| >5                           | 9 (20.5)             | 20 (15.2)         |         |
| Diabetes mellitus, n (%)     | 8 (18.2)             | 30 (22.7)         | 0.673   |
| Liver disease, n (%)         | 5 (11.4)             | 27 (20.5)         | 0.258   |
| Residential status prior to admission, n (%) | 0.362              |                   |         |
| Home                         | 36 (81.8)            | 109 (82.6)        |         |
| Nursing home or long-term care facility | 2 (4.6)           | 3 (2.3)           |         |
| Chronic care hospital        | 2 (4.6)              | 2 (1.5)           |         |
| Acute care hospital          | 4 (9.1)              | 18 (13.6)         |         |
| Healthcare exposure within 30 days, n (%) | 42 (95.5)         | 115 (87.1)        | 0.164   |
| History of hospitalization within 90 days, n (%) | 30 (68.2)         | 52 (39.4)         | 0.002   |
| Characteristic                                                                 | Group 1 (n, %) | Group 2 (n, %) | P-value |
|-------------------------------------------------------------------------------|----------------|----------------|---------|
| History of chemotherapy within 28 days, n (%)                               | 8 (18.2)       | 7 (5.3)        | 0.013   |
| History of steroid use within 28 days, n (%)                                | 20 (45.5)      | 21 (15.9)      | <0.001  |
| Any antimicrobial allergy, n (%)                                            | 5 (11.4)       | 17 (12.9)      | 1.000   |
| Surgery performed prior to PPRF during index hospitalization, n (%)          | 1 (2.3)        | 36 (27.3)      | <0.001  |
| Chemotherapy performed prior to PPRF during index hospitalization, n (%)     | 8 (18.2)       | 23 (17.4)      | 1.000   |
| Steroid use prior to PPRF during index hospitalization, n (%)                | 19 (43.2)      | 39 (29.6)      | 0.100   |
| HSCT performed prior to PPRF during index hospitalization, n (%)             | 5 (11.4)       | 6 (4.6)        | 0.145   |
| History of MDRO acquisition within 1 year before PPRF, n (%)                | 9 (20.5)       | 23 (17.4)      | 0.656   |
| Clinical and laboratory characteristics at the time of PPRF                  |                |                |         |
| Onset, n (%)                                                                 |                |                | 0.141   |
| Community, non-healthcare-associated                                         | 14 (31.8)      | 23 (17.4)      |         |
| Community, healthcare-associated                                             | 5 (11.4)       | 18 (13.6)      |         |
| Nosocomial                                                                    | 25 (56.8)      | 91 (68.9)      |         |
| Antimicrobial use prior to initiation of PPRF                                | 34 (77.3)      | 87 (65.9)      | 0.191   |

Downloaded from https://academic.oup.com/ofid/article-abstract/doi/10.1093/ofid/ofaa298/5872668 by guest on 20 July 2020
|                          | Prescribers, n (%)  |
|--------------------------|-------------------|
| **Antimicrobials, n (%)**|                   |
| Department, n (%)        |                   |
| Medicine                 | 29 (65.9)         |
|                          | 66 (50.0)         |
| Critical care medicine   | 9 (20.5)          |
|                          | 16 (12.1)         |
| Surgery                  | 6 (13.6)          |
|                          | 50 (37.9)         |
| ICU stay, n (%)          | 9 (20.5)          |
|                          | 19 (14.4)         |
| Rapidly fatal McCabe score, n (%) | 21 (47.7) |
|                          | 30 (22.7)         |
| ANC <500 /μL, n (%)      | 2 (4.6)           |
|                          | 6 (4.6)           |
| WBC, median, (IQR) ×10^3/μL | 7.9 (5.5-11.0)  |
|                          | 6.9 (4.2-10.8)    |
| CRP, median, (IQR) mg/dL | 4.6 (1.9-9.4)     |
|                          | 4.4 (1.5-8.9)     |
| Mechanical ventilation use, n (%) | 4 (9.1) |
|                          | 11 (8.3)          |
| Vasopressor use, n (%)   | 4 (9.1)           |
|                          | 7 (5.3)           |
| Central venous catheter use, n (%) | 16 (36.4) |
| ECMO, n (%)              | 2 (4.6)           |
|                          | 3 (2.3)           |
| Prescribers’ PGY, n (%)  |                   |
| 1-3                      | 2 (4.6)           |
|                          | 25 (18.9)         |
| 4-7                      | 26 (59.1)         |
|                          | 72 (54.6)         |
| >7                       | 16 (36.4)         |
|                          | 35 (26.5)         |
| Male prescribers, n (%)  | 34 (77.3)         |
|                          | 97 (73.5)         |

**P-values:**
- 0.007
- 0.348
- 0.002
- 1.000
- 0.474
- 0.709
- 1.000
- 0.471
- 0.578
- 0.600
- 0.043
- 0.693
Prescribing decision made by, n (%)  

|            | Single physician | Team |
|------------|------------------|------|
|            | 32 (72.7)        | 12 (27.3) |
|            | 74 (56.1)        | 58 (43.9) |

0.053

Abbreviations: *IQR*, interquartile range; *PPRF*, post-prescription review with feedback; *HSCT*, hematopoietic stem cell transplantation; *MDRO*, multidrug-resistant organism; *ICU*, intensive care unit; *ANC*, absolute neutrophil count; *WBC*, white blood cell; *CRP*, C-reactive protein; *ECMO*, extra-corporeal membrane oxygenation; *PGY*, postgraduate year
Table 2. Factors associated with non-adherence to PPRF intervention

|                        | Univariate analyses, OR (95%CI) | P value | Multivariate analyses, aOR (95%CI) | P value |
|------------------------|---------------------------------|---------|-----------------------------------|---------|
| Charlson comorbidity index score |                                 |         |                                   |         |
| <2                     | Ref.                            |         |                                   |         |
| 2-5                    | 2.62 (0.93-7.32)                | 0.067   |                                   |         |
| >5                     | 3.06 (0.90-10.41)               | 0.074   |                                   |         |
| History of hospitalization within 90 days | 3.30 (1.52-7.36)               | 0.002   | 2.62 (1.18-5.81)                  | 0.018   |
| Surgery performed prior to PPRF during index hospitalization | 0.06 (0.01-0.47)               | <0.001  |                                   |         |
| Department at the time of PPRF |                                 |         |                                   |         |
| Medicine               | Ref.                            |         |                                   |         |
| Critical care medicine | 1.28 (0.51-3.23)               | 0.601   |                                   |         |
| Surgery                | 0.27 (0.11-0.71)                | 0.008   |                                   |         |
| Rapidly fatal McCabe score at the time of PPRF | 3.10 (1.42-6.75)               | 0.002   | 2.87 (1.18-6.98)                  | 0.020   |

Prescribers’ PGY

1-3 Ref.
| Value | Odds Ratio (95% CI) | P Value |
|-------|--------------------|---------|
| 4-7   | 4.5 (0.99-20.40)   | 0.050   |
| >7    | 5.71 (1.20-27.11)  | 0.028   |

Prescribing decision made by single physician 2.10 (0.94-4.85) 0.053

Abbreviations: PPRF, post-prescription review with feedback; OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; Ref., reference; PGY, postgraduate year.

Note: The Hosmer-Lemeshow test was used for goodness-of-fit for logistic regression with a \( P \) value of 0.38. Variables considered but not included in the multivariate analysis due to multicollinearity and limited events were a history of chemotherapy within 28 days, history of steroid use within 28 days, and past medical history of diabetes mellitus or liver disease.
### Table 3. Adverse events and outcomes

|                                | Non-adherence (n=44) | Adherence (n=132) | P value |
|--------------------------------|----------------------|-------------------|---------|
| Total duration of antimicrobial therapy during index hospitalization, median, (IQR) days | 16 (10-42)  | 14 (10-28)  | 0.302 |
| Total duration of PPRF antimicrobial therapy during index hospitalization, median, (IQR) days | 12 (10-19)  | 11 (6-16)  | 0.063 |
| CDI developing within 3 months after PPRF, n (%) | 2 (4.6)  | 3 (2.3)  | 0.600 |
| AKI developing within 1 month after PPRF, n (%) | 12 (29.3)  | 20 (16.8)  | 0.112 |
| MDRO acquisition after PPRF during index hospitalization, n (%) | 2 (4.6)  | 11 (8.3)  | 0.522 |
| LOS from the date of PPRF to discharge, median, (IQR) days | 21 (10-54)  | 21 (8-43)  | 0.637 |
| LOS from the date of admission to PPRF, median, (IQR) days | 16 (8-36)  | 15 (7-26)  | 0.421 |
| In-hospital mortality, n (%) | 8 (18.2)  | 19 (14.4)  | 0.629 |
| Re-admission within 1 month after discharge, n (%) | 7 (15.9)  | 15 (11.4)  | 0.436 |

Abbreviations: IQR, interquartile range; PPRF, post-prescription review with feedback; CDI, *Clostridioides difficile* infection; AKI, acute kidney injury; MDRO, multidrug-resistant
organism; *LOS*, length of stay
Table 4. Reasons for non-adherence to post-prescription review and feedback intervention

| Reasons                                                                 | %  (n=44)   |
|-------------------------------------------------------------------------|-------------|
| **Patient-related factors**                                             |             |
| “The patient was sick.”                                                 | 27.3% (n=12) |
| “The patient was immunocompromised.”                                    | 15.9% (n=7)  |
| “The patient was colonized with an MDRO.”                               | 9.1% (n=4)   |
| “The patient was scheduled to be transferred or discharged soon.”       | 9.1% (n=4)   |
| “The patient had neutropenia.”                                          | 2.3% (n=1)   |
| “The patient’s CRP level was high.”                                     | 2.3% (n=1)   |
| “The patient was allergic to multiple antimicrobials.”                   | 2.3% (n=1)   |
| **Prescriber-related factors**                                          |             |
| “The antimicrobial seemed to be clinically effective.”                   | 20.5% (n=9)  |
| “I would like to continue giving antimicrobials, just in case.”         | 2.3% (n=1)   |
| “The primary care provider was unavailable.”                             | 2.3% (n=1)   |
| **Unknown**                                                             | 6.8% (n=3)   |

Abbreviations: MDRO, multidrug-resistant organism; CRP, C-reactive protein